Eczacibasi Ilac Sanayi ve T.A.S. operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eczacibasi Ilac Sanayi ve T.A.S. with three other
pharmaceutical manufacturers in Europe:
Horizon Discovery Group PLC
of the United Kingdom
sales of £36.51 million [US$45.87 million]
of which 62%
Moberg Pharma AB (publ)
(439.03 million Swedish Kronor [US$48.27 million]
of which 35%
was Kerasal Nail /Nalox), and
based in France
(105.29 million Euro [US$119.51 million]
of which 88%
was Commercialized Vaccines).
Eczacibasi Ilac Sanayi ve T.A.S. reported sales of 597.91 million Turkish Liras (US$112.29 million)
December of 2017.
decrease of 57.7%
versus 2016, when the company's sales were 1.41 billion Turkish Liras.
Contributing to the drop in overall sales was the 90.0% decline
in Personal Care, from 1.05 billion Turkish Liras to 104.62 million Turkish Liras.
However, these declines were partially offset by the increase in sales of
Health (up 12.0% to 427.50 million Turkish Liras)